key: cord-0011399-yh1cag8q
authors: Abdul-Aziz, Mohd H.; Alffenaar, Jan-Willem C.; Bassetti, Matteo; Bracht, Hendrik; Dimopoulos, George; Marriott, Deborah; Neely, Michael N.; Paiva, Jose-Artur; Pea, Federico; Sjovall, Fredrik; Timsit, Jean F.; Udy, Andrew A.; Wicha, Sebastian G.; Zeitlinger, Markus; De Waele, Jan J.; Roberts, Jason A.
title: Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper(#)
date: 2020-05-07
journal: Intensive Care Med
DOI: 10.1007/s00134-020-06050-1
sha: f5e3fe97eb1c58db866bcad540ba3d3a50b1521c
doc_id: 11399
cord_uid: yh1cag8q

PURPOSE: This Position Paper aims to review and discuss the available data on therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients in the intensive care unit (ICU). This Position Paper also provides a practical guide on how TDM can be applied in routine clinical practice to improve therapeutic outcomes in critically ill adult patients. METHODS: Literature review and analysis were performed by Panel Members nominated by the endorsing organisations, European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC). Panel members made recommendations for whether TDM should be applied clinically for different antimicrobials/classes. RESULTS: TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established, and for these agents, routine TDM in critically ill patients appears meritorious. For the antivirals, research is needed to identify therapeutic targets and determine whether antiviral TDM is indeed meritorious in this patient population. The Panel Members recommend routine TDM to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients. CONCLUSION: Although TDM should be the standard of care for most antimicrobials in every ICU, important barriers need to be addressed before routine TDM can be widely employed worldwide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00134-020-06050-1) contains supplementary material, which is available to authorized users.

Despite numerous therapeutic innovations, infectionrelated mortality in critically ill patients persists as a significant healthcare concern. Given the corresponding high burden of infection, it is unsurprising that the consumption of antimicrobial agents (antibacterials, antifungals and antivirals) in the intensive care unit (ICU) is ten times higher than in other wards [1] . It is essential to optimise the use of antimicrobial agents not only to maximise therapeutic success but also to prolong the clinical lifespan of these currently available drugs by limiting the emergence of resistance [2] . However, the process of optimising antimicrobial therapy (including both spectrum and therapeutic exposure) is a massive challenge in ICU patients, who often manifest extreme inter-and intraindividual pharmacokinetic (PK) variability [3] . It follows that conventional antimicrobial dosing may risk clinical failure in this patient population as most dose-finding studies only included non-ICU populations. Indeed, perhaps more than in any other patient population, nonoptimised antimicrobial dosing may more commonly lead to low drug exposure and therapeutic failure and/or antimicrobial resistance [4] , or high drug exposure, leading to an increased risk of toxicity.

With an expanding knowledge on the relationships between antimicrobial dosing, pharmacokinetic/pharmacodynamic (PK/PD) exposure and patient outcomes, there is now a strong rationale to individualise antimicrobial dosing in critically ill patients with the aid of therapeutic drug monitoring (TDM). Traditionally, TDM was only employed to minimise the likelihood of toxicity in drugs with narrow therapeutic indices (e.g. aminoglycosides and vancomycin) and in drugs with complex pharmacokinetics (e.g. voriconazole) and has been hitherto underused for other antimicrobials. However, the recent surge in multidrug-resistant pathogens causing infections, combined with a declining antimicrobial pipeline, is causing a need to revise this approach. TDM of antimicrobials, even for those with a wide therapeutic index, is becoming more common [5, 6] , whilst TDM for the "traditional" drugs, such as aminoglycosides and glycopeptides, is continually being studied for further improvement.

Currently, there is significant variation across institutions on how TDM is applied in terms of antimicrobial and patient selection, sampling time points and antimicrobial assays for concentration monitoring, as well as PK/PD targets and the approach to dose modification [5, 6] . This Position Paper aims to review and discuss the available data on TDM of antibacterials, antifungals and antivirals in critically ill adult patients. This Paper will also provide a practical guide on how antimicrobial TDM can be applied in everyday clinical practice to improve therapeutic outcomes in critically ill adult patients. Finally, the Panel aims to recommend antimicrobials for which TDM should be routinely performed in critically ill patients.

The Position Paper Panel members were nominated by the endorsing organisations including European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/ Pharmacodynamic (PK/PD) and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC).

This Position Paper was developed following a review of studies published in English before 1 July 2019. A literature search was performed on PubMed with no date restrictions using the following MeSH terms: ("antibacterial agents" OR "antifungal agents" OR "antiviral agents") AND ("drug monitoring" OR "pharmacokinetics" OR "pharmacodynamics") AND ("critical care" OR "critical illness" OR "intensive care units"). The search was also performed for each antimicrobial (e.g. meropenem) and antimicrobial class of interest (e.g. carbapenems). For clinical efficacy and toxicity, only studies on critically ill adult patients were reviewed and included in the analysis.

The Panel members held face-to-face meetings and teleconferences to formulate the structure and content of this Position Paper. Members were divided into groups consisting of a lead author and co-authors for each section. Each group was tasked to review the literature, evaluate the available data and summarise their findings in a draft document addressing whether TDM is indicated for a particular antimicrobial/antimicrobial class in critically ill patients. All members reviewed the full draft document, and discrepancies were discussed and resolved by consensus.

A seven-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = somewhat disagree, 4 = neutral, 5 = somewhat agree, 6 = agree and 7 = strongly agree) was used to score the recommendation of the Panel for performing TDM for each antimicrobial/antimicrobial class in critically ill patients. Consensus was achieved when the sum of 1 and 2 (negative consensus) or 6 and 7 (positive consensus) was ≥ 75%.

Critically ill patients are those patients whose conditions are life-threatening and require specialised care in the ICU. Such patients require intensive monitoring and treatment due to failure of vital organ functions (due to acute and/or chronic disease) or due to the sequelae of surgical or other intensive treatment associated with lifethreatening conditions. Critical illness is characterised by marked homoeostatic changes, driven by both the underlying disease process and the interventions required. These features profoundly affect organ function, resulting in a pathophysiological state that is not encountered in an ambulatory setting. Moreover, the presence of chronic comorbidity can further exacerbate the pathophysiological changes commonly encountered during critical illness. All of these factors will significantly influence antimicrobial PK in the critically ill and can be broadly considered in terms of altered volume of distribution (V d ) and drug clearance (CL).

Endothelial dysfunction is common in critical illness and is characterised by expansion of the interstitial space through "capillary leakage". This is closely linked to the severity of the underlying disease process and the degree of systemic inflammation. Sepsis and major burn injury are classic examples. This is then further exacerbated by intravenous (IV) fluid loading, a near-ubiquitous intervention in the ICU. For hydrophilic antimicrobials (e.g. acyclovir, aminoglycosides, beta-lactams, daptomycin, fluconazole and glycopeptides), this can result in a significantly expanded V d [7] . Changes in protein binding associated with hypoalbuminaemia will also potentially influence antimicrobial PK [8] . Indeed, hypoalbuminaemia is commonly encountered (as a negative acute phase reactant), resulting in an increase in the V d for highly protein-bound antimicrobials, such as ceftriaxone, daptomycin, ertapenem, flucloxacillin and teicoplanin [8] . In these scenarios, the free (or unbound) fraction is increased, resulting in both greater distribution and potentially CL. Finally, extremes of body size and composition (typically obesity) will also influence V d , although the magnitude of any such change will depend on the physicochemical properties of the antimicrobial (e.g. molecular weight, lipid solubility and degree of ionisation) [9] .

Many commonly prescribed antimicrobials are principally cleared by renal elimination. In this context, critical illness can have a profound impact on renal function and therefore drug CL. Augmented renal clearance (ARC) is being increasingly noted in critically ill sub-populations (incidence of 14-80%) [10] . ARC is defined as an increased creatinine clearance > 130 mL/min/1.73 m 2 measured by 8-24-h urine collection and refers to the enhanced renal elimination of circulating solute (such as metabolic waste and drugs) [11] . The underlying mechanisms are uncertain, although increased solute delivery related to a hyperdynamic high cardiac output state, in combination with tubular and/or neuroendocrine changes, is likely implicated [10] . Identifying patients with ARC is challenging as these patients may have elevated renal function despite normal serum creatinine concentrations [12] , and importantly, commonly used glomerular filtration rate mathematical estimates, such as the Cockcroft-Gault and Modified Diet in Renal Disease equations, are unlikely to be reliable as compared to urinary creatinine clearance data [13] . Younger patients with multiple trauma are at the highest risk [12] , but ARC has also been described in other patient categories. Moreover, the presence of ARC has been associated with sub-optimal plasma antimicrobial concentrations [11] , although the implications in terms of clinical outcomes remain unclear [14] .

In contrast, many critically ill patients will develop acute kidney injury, requiring the use of renal replacement therapy (RRT). In the acute setting, continuous veno-venous techniques are most frequently used, with variable fractions of filtration and/or dialysis. Factors such as molecular weight, protein binding, hydrophilicity, mode of RRT, filter porosity, surface area, blood flow rate and total effluent rate will all influence extracorporeal drug handling [15] . Given the heterogeneity in clinical practice and pathophysiology, antimicrobial dosing is generally empiric, resulting in substantial intra-and inter-patient variability in drug concentrations [16] . The intensity of RRT and any residual native renal function are likely to be the most important variables in determining renal drug CL in this setting [17] .

Other extracorporeal circuits (such as extracorporeal membrane oxygenation) may also contribute to altered drug CL, depending on the degree of adsorption, and any co-existing renal dysfunction [18] .

For antimicrobials, PD links PK exposure with its ability to kill or inhibit the growth of a pathogen. This relationship can be described by relating the PK exposure of an antimicrobial to the minimum inhibitory concentration (MIC) of the offending pathogen. Antimicrobials classically have different PK/PD indices [19] , and these can be categorised as: (a) the ratio of maximum drug concentration (C max ) to MIC (C max /MIC); (b) the duration of time (T) that the free drug concentration remains above the MIC during a dosing interval (fT >MIC ); and (c) the ratio of the area under the concentration-time curve during a 24-hour period to MIC (AUC 0-24 /MIC) [20] . However, it is also important to note that individual MICs were rarely measured in most of the earlier studies and parameters such as MIC 50 and MIC 90 were used instead to describe the PK/PD relationships. For antivirals, in particular, measures other than the MIC have been used as the denominator of the PK/PD index such as the in vitro concentration required to obtain 50% of the maximum effect (EC 50 ). The denominator in these indices is an important consideration because when it increases, the corresponding PK exposure should also be increased to ensure that the optimal PK/PD index is still achieved. This is mostly relevant in the ICU as at least bacterial pathogens may demonstrate higher MICs, as much as 2-4 times higher, when compared to the general wards [21] .

Importantly, a recent review by Mouton et al. highlights that the use of an individual MIC to guide antibacterial dosing may not be appropriate due to imprecise and highly variable (varying by 1-2 dilutions in both directions) measurements associated with MIC determination [22] . Therefore, an individual MIC measurement should only be regarded as an estimate and not a "true" value of a pathogen's susceptibility. MIC may vary according to determination methods (e.g. broth microdilution vs. E-test ® ), and it is therefore important to aim for an appropriate MIC method-specific target, with broth microdilution (BMD) MIC being the preferred method, if they are available. Any potential dosing adjustments with the aid of TDM must consider MIC variation and should be interpreted in the context of assay variation, species identification and wild-type distributions. Measures of MIC distributions such as epidemiologic cut-off (ECOFF) values, which separate bacterial populations into those of a wild-type population and those with either a low-or high-level phenotypically detectable resistance, can be more useful to guide antibacterial dosing. Mouton et al. proposed several practical solutions in their review to optimise antibacterial dosing for patients, and one of the important recommendations included the use of ECOFF values as the PD target for dosing purposes when the measured MIC for the bacterial strain is within the wild-type distribution [22] . If the MIC is slightly above the ECOFF, a two-fold dilution of the MIC can be assumed for dosing purposes, whilst MIC-guided therapy should not be an option if the measured MIC is clearly far above the ECOFF and clinical resistance breakpoint.

An antimicrobial should fulfil certain criteria for TDM to be of potential benefit and some of these criteria include: (a) a significant intra-and/or inter-individual PK variability; (b) a defined exposure range associated with pharmacological responses (clinical responses and toxicities); (c) defined relevant sampling time points; and (d) accurate and timely bioanalytical assay methods for drug measurement.

Critically ill patients often demonstrate extreme variability in antimicrobial PK, which can be partly explained by patient covariates (e.g. body weight and renal function). Unexplained PK variability can be observed across patients (i.e. inter-individual variability) and also, within a patient (i.e. intra-individual PK variability). TDM-based dosing adjustment is clinically useful for an antimicrobial if the unexplained inter-individual PK variability exceeds the intra-individual variability. Otherwise, solely applying covariate-based dosing strategies would be sufficient, as is the case with Product Information and nomogrambased dosing.

PK sampling for antimicrobial TDM is traditionally performed at the end of each dosing interval to obtain a trough sample (minimum concentration in dosing interval, C min ). Whilst C min provides some information on drug CL, determination of V d requires an additional sample earlier in the dosing interval. For the estimation of derived PK parameters, such as the AUC, and PK/PD targets, such as the fT >MIC , an optimised PK sampling schedule is suggested for unbiased and precise parameter estimation. A limited sampling strategy (LSS), which uses the most "informative" concentration-time points (commonly 1-3 sampling time points) to describe a drug's PK, is relatively easy to be performed and may provide accurate estimates of full drug exposure [23, 24] . The optimal sampling time points for a drug can be identified during "limited sampling" studies where these time points will be estimated or calculated using PK models and Monte Carlo simulations. The time points can then be used to predict AUC 0-24 , and as such, this approach is beneficial for those antimicrobials in which AUC 0-24 /MIC ratios are the major determinants for efficacy. For example, although 10-15 time points are conventionally needed to calculate 80% of the total AUC, Alsultan et al. demonstrated that these can be reduced to only 2 time points (sampling at 4 and 6 h post-dose) with LSS to estimate levofloxacin AUC [25] . For antibacterials that are administered via continuous infusion, a sample at any given time during administration can be used.

Ideally, measuring antimicrobial concentration at the site of infection (e.g. epithelial lining fluid in pneumonia and cerebrospinal fluid in meningitis) is preferred as most antimicrobial-pathogen interactions are thought to occur here. However, due to practical limitations, most centres have been using plasma concentrations as a surrogate for concentrations at the actual site of infection. Importantly, some antimicrobials are unevenly distributed and plasma concentration does not always reflect concentrations at the infected tissues.

Bioanalytical assays for measuring antimicrobial concentrations should be precise, accurate, highly selective for a particular drug and, importantly, available in a timely manner (e.g. turnaround times of < 8 h, preferably shorter or within the same day of sampling). Regular quality control exercises through proficiency testing programs are recommended to ensure that the assays have sufficient accuracy, precision and specificity for routine TDM and patient management [26, 27] . Ideally, free drug concentrations should be measured at physiologically relevant conditions [28] and reported, but due to practical limitations, most laboratories report only total concentrations. Further to this, exposure targets for some drugs have only been defined in terms of total exposure (e.g. vancomycin).

TDM-based dosing adjustments can be performed in several different ways. Whilst it is still popular to compare and evaluate a single drug concentration (e.g. C min ) against a therapeutic target range, and this method is the easiest, it is the least accurate method for dosing adjustment. Dosing nomograms, on the other hand, can integrate PK/PD data with measures of organ function (e.g. renal function described using creatinine clearance) and have demonstrated to be superior to conventional antimicrobial dosing [29, 30] . However, separating the sources of PK variability and incorporating > 1 covariate for dosing adjustments (e.g. creatinine clearance and weight) are not possible with a single dosing nomogram. Additionally, the dose prediction from such nomograms would be inaccurate if the pre-defined PK sampling/dosing schedule is not strictly adhered to. The use of dosing software overcomes these limitations [2] , and these methods have been shown to be superior over conventional antimicrobial dosing for vancomycin [31] , particularly in the context of:

(a) the first dose can initially be individualised for patients by using Monte Carlo simulations; (b) the sources of PK variability can be separated into intra-and inter-individual variability; (c) PK sampling before reaching steady state is possible; and (d) through Bayesian estimation, the entire antimicrobial PK profile can be estimated from a single PK sample. Bayesian estimation is most accurate when an optimal sampling time is chosen to provide the most information about the drug's PK behaviour in the patient and a suitable population PK model matching the target population to serve as the Bayesian prior model [32] . After initial TDM, it is recommended to repeat TDM (within 1-2 days for most drugs) to confirm therapeutic exposures have been achieved and again thereafter if there are concerns of significant changes to PK (e.g. enteral absorption, renal function).

The following sections describe the specific TDM data relating to various antimicrobial classes. Tables 1, 2 and 3 describe optimal PK/PD indices and magnitudes associated with clinical efficacy and toxicity of antibacterials, antifungals and antivirals, respectively. TDM recommendations for each antimicrobial are summarised in Table 4 . Table 5 highlights relevant studies/data that demonstrate clinical outcome benefits of antimicrobial TDM. The primary data that support each recommendation and the suggested empirical dosing of these antimicrobials in critically ill patients are included in Supplementary Tables. We highly recommend readers to use the information presented in the following sections in conjunction with the data presented in Tables 1, 2, 3, 4 and 5, as well as those presented in Supplementary Tables 1-5, for specific suggestions on how TDM can be performed for a particular antimicrobial/antimicrobial class in critically ill patients.

Aminoglycosides are hydrophilic with a low V d and CL that is proportional to glomerular filtration rate. Significant V d and CL alterations have been widely described in critically ill patients.

Aminoglycosides demonstrate "concentration-dependent" bactericidal activity, which is optimal when the C max is ≥ 8-10 × MIC [33] [34] [35] . Recent data, however, have suggested that the AUC 0-24 /MIC ratio might be a better predictor of activity and is better suited to judge target attainment in extended-interval dosing of aminoglycosides. High C min and AUC exposures over days have been associated with oto-and nephrotoxicity.

High, single-dose, extended-interval dosing should be used in patients with Gram-negative infections. Recent data suggest that higher-than-standard aminoglycoside dosing regimen may be required for critically ill patients [36, 37] .

The Panel recommends that TDM be routinely performed when aminoglycosides are used in critically ill patients. AUC-based monitoring with at least two time points collected combined with Bayesian dose adaptation best predicts aminoglycoside dosing requirements [38] [39] [40] . TDM-guided dosing with Bayesian dose adaptation has led to a shorter length of hospital stay and a reduced incidence of nephrotoxicity in patients receiving gentamicin for Gram-negative infections [39] .

Commercial immunoassays are available for amikacin, gentamicin and tobramycin TDM. For other aminoglycosides (e.g. kanamycin and plazomicin), modified immunoassays or chromatographic assays need to be established.

Beta-lactam antibacterials are generally hydrophilic, demonstrate low V d and are predominantly cleared via renal elimination. Most beta-lactams have a moderate (30-70%) to low (< 30%) degrees of protein binding. Significant V d and CL alterations are common, and these PK 

No data alterations may lead to inadequate beta-lactam concentrations particularly in the earlier phase of critical illness. Hypoalbuminemia has been associated with an increase in the free fraction (non-protein bound) of highly protein-bound beta-lactams (e.g. ceftriaxone, ertapenem and semisynthetic penicillins such as flucloxacillin, oxacillin and temocillin) and low unbound concentrations towards the end of the dosing interval [8] .

The PK/PD index associated with optimal beta-lactam activity is the % fT >MIC (40-70%). Critically ill patients data suggest that patients may benefit from longer (e.g. 100% fT >MIC ) [41] [42] [43] and higher (e.g. 2-5 × MIC) [42] [43] [44] beta-lactam exposures than those previously described. Although the beta-lactams generally have a wide therapeutic index, high exposures have been associated with neurotoxicity. Although myelosuppression is well-known toxicity for the beta-lactams [45] , no toxicity thresholds have been well established to date.

An initial loading dose (LD) followed by prolonged betalactam infusion (continuous or extended infusion) maximises PK/PD target attainment and is likely to improve clinical outcomes in critically ill patients [46] .

The Panel recommends that TDM be routinely performed when beta-lactam antibiotics are used in critically ill patients.

The collateral damage of more aggressive beta-lactam dosing to account for altered drug PK, i.e. excessive drug exposure, has been increasingly reported over the last 10 years, although it is probably still under-reported. TDM of beta-lactam antibiotics in critically ill patients is, therefore, becoming more common to optimise dosing whilst minimising the likelihood of toxicity [5, 47] . C min samples at steady state are widely used, although the use of dosing software could enable even earlier sampling and dose optimisation [48] . 

Several high-performance liquid chromatography with ultraviolet detection (HPLC-UV) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays have been applied to beta-lactam TDM.

Co-trimoxazole consists of a combination of sulfamethoxazole and trimethoprim in a 5:1 ratio. Both drugs are predominantly cleared by renal elimination and are moderately bound to plasma proteins. Although the impact of critical illness on its PK has been scarcely reported, significant PK variability has been observed with weightbased dosing of co-trimoxazole in older studies [49, 50] .

C max and fAUC 0-24 /MIC ratios have been linked with optimal sulfamethoxazole/trimethoprim activity. Higher doses and exposures may likely increase the likelihood of adverse events such as hyperkalemia and metabolic acidosis.

There are insufficient clinical data to support altering cotrimoxazole dosing for maximal outcomes in critically ill patients. Weight-based dosing depending on the pathogen is appropriate.

The Panel neither recommends, nor discourages routine sulfamethoxazole (as the representative drug in co-trimoxazole) TDM in critically ill patients.

No commercial assays are currently available, and a chromatographic assay is required to facilitate TDM.

Daptomycin demonstrates a low V d and is predominantly cleared via renal elimination. V d and CL alterations are common, leading to variable and low drug exposure. It is a highly protein-bound drug (92-94%) and the free fraction increases in critically ill patients.

AUC 0-24 /MIC ratios of ≥ 666 mg/L have been described for daptomycin efficacy in critically ill patients [51] . More recently, a C min of < 3.2 mg/L has been linked to poor clinical outcomes in hospitalised patients with various Gram-positive infections [52] . A C min of ≥ 24.3 mg/L is associated with an increased likelihood of creatine phosphokinase (CPK) elevation by > 30-fold [53] .

Current data suggest that optimal AUC 0-24 /MIC ratios can easily be achieved with a Product Information dose of 6 mg/kg but only for pathogens with an MIC of 0.1 mg/L. With increasing MICs, higher doses (10-12 mg/kg/day) are probably required to achieve these targets [51, 54, 55] .

The Panel neither recommends, nor discourages routine daptomycin TDM in critically ill patients. As daptomycin presents highly variable and unpredictable PK, several centres have performed TDM and have reported their clinical experience [52, 56, 57] . Previous work has aimed for C min < 24 mg/L at steady-state [52, 57] . AUC-based monitoring, via LSS, can also be applied to guide daptomycin dosing to achieve AUC 0-24 /MIC ratios of ≥ 666 [58] .

Fluoroquinolones are moderately lipophilic with V d generally unaffected by critical illness, with the exception of levofloxacin. Most fluoroquinolones have a moderate to low degree of protein binding, and some are cleared, at least to some degree, by renal elimination.

Fluoroquinolones exhibit "concentration-dependent" bactericidal activity, and the AUC 0-24 /MIC ratio best predicts clinical efficacy. Higher C max /MIC ratios (> 8-20) may also be required for optimal bactericidal activity [59, 60] . AUC 0-24 /MIC ratios of 25-30 may suffice against the Gram-positive organisms, but higher values (≥ 125) are needed against the Gram-negative organisms [61, 62] . Several studies have also suggested that a ratio of > 100-200 may suppress the emergence of resistance against Gram-negative organisms. Although increasing reports of fluoroquinolones-associated seizures have emerged [63] [64] [65] , no toxicity thresholds have been established and causality is debated [66] .

A quinolone dosing regimen that maximises the AUC 0-24 /MIC (e.g. LD with higher maintenance doses) should be considered in critically ill patients.

The Panel neither recommends, nor discourages routine fluoroquinolone TDM in critically ill patients.

Given the inter-individual PK variability reported in critically ill patients and the high propensity for emergence of resistance against quinolones, TDM may be useful, particularly where pathogens have MICs close to the susceptibility breakpoint.

HPLC and LC-MS/MS assays have been published for fluoroquinolones TDM.

Teicoplanin is hydrophilic, with a V d of 0.7-1.4 L/kg, and is predominantly cleared via renal elimination. It has a long elimination half-life (t ½ ) due to its high plasma protein binding (≥ 90%). Variability of teicoplanin exposure is significant in critically ill patients [67] [68] [69] .

A C min of ≥ 10-20 mg/L has been associated with favourable clinical response in uncomplicated infection [70, 71] , but higher concentrations (≥ 20-30 mg/L) are advocated for severe Staphylococcal infections including endocarditis and osteomyelitis. However, the clinical data supporting these higher concentrations are sparse. More recent data suggested that the AUC 0-24 /MIC ratio (≥ 750) may better predict teicoplanin activity in serious methicillinresistant S. aureus (MRSA) infections [72, 73] . Unpublished studies reported that a C min of > 60 mg/L increased the likelihood of nephrotoxicity.

Teicoplanin has a long t ½ (150 h) with the use of LD essential to reduce the time to reach therapeutic exposures.

The Panel recommends that TDM be routinely performed when teicoplanin is used in critically ill patients.

Vancomycin is hydrophilic, demonstrates a low V d and is predominantly cleared via renal elimination. Critical illness alters the V d and CL of vancomycin leading to variable and low drug exposure.

AUC 0-24 /MIC ratios of ≥ 400 are recommended against Staphylococcus aureus infection, whereas higher exposures are advocated when treating critically ill patients with septic shock [74] [75] [76] . Prolonged (≥ 7 days) and high vancomycin exposures are associated with nephrotoxicity.

Safely attaining optimal AUC 0-24 /MIC ratios when treating pathogens with MICs of > 1 mg/L is highly challenging with vancomycin [77] . LD of 25-30 mg/kg, followed by 15-20 mg/kg every 8-12 h should be considered in critically ill patients without renal impairment. Continuous vancomycin infusion has been associated with a lower nephrotoxicity risk [78, 79] , but clinical superiority has yet to be demonstrated over intermittent dosing. For practical reasons and ease of TDM, however, continuous vancomycin infusion is sometimes preferred and has been increasingly used in some centres.

The Panel recommends that TDM be routinely performed when vancomycin is used in critically ill patients.

Monitoring C min (15-20 mg/L for intermittent infusion) or average steady-state concentration (C ss , 20-25 mg/L for continuous infusion) for pathogens with MIC ≤ 1 mg/L has been widely used as a surrogate for the AUC 0-24 /MIC target. However, current data have demonstrated that C min is a poor surrogate for AUC 0-24 and may tend to underestimate the actual vancomycin exposure [31, [80] [81] [82] [83] . AUC-based monitoring with Bayesian dose adaptation may likely be a better tool to guide vancomycin treatment in critically ill patients. Although the contemporary AUC 0-24 /MIC target has always been approximated as ≥ 400 for vancomycin, this index was derived from BMD MIC, and the E-test equivalence to this might only be 226 [84] .

Immunoassays are commercially available for vancomycin TDM.

Linezolid is moderately lipophilic, demonstrates a V d that approximates the total volume of total body water, is predominantly cleared via non-renal elimination and demonstrates significant intra-and inter-patient PK variability leading to variable linezolid exposure.

Maximum efficacy is demonstrated at % T >MIC of ≥ 85% and AUC 0-24 /MIC ratio of 80-120 [85] . Linezolidinduced thrombocytopenia has been reported at C min and AUC 0-24 of > 7-10 and > 300-350, respectively.

Critically ill patients may benefit from higher linezolid doses and/or altered dosing approaches (e.g. front-loaded dosing regimen and continuous infusion) although these approaches should be supported with TDM if available. Subgroups of patients who may likely require higherthan-standard linezolid doses include those who are obese, those with acute respiratory distress syndrome and ARC, as well as those who are infected with pathogens with MIC ≥ 2 mg/L [54, 86] .

The Panel recommends that TDM be routinely performed when linezolid is used in critically ill patients.

Using an epidemiological MIC distribution, a C min target of > 2 mg/L is well correlated with an AUC 0-24 /MIC ratio of ≥ 80 [87] . Therefore, maintaining linezolid C min between 2 and 7 mg/L is recommended for optimal drug exposure whilst minimising haematological toxicity [88] . Alternatively, TDM via LSS can be used [89] .

HPLC-UV, LC-MS/MS and immunoassays have been published, but these assays are currently sparsely implemented for routine TDM.

Colistin is administered parenterally as the prodrug colistin methanesulfonate (CMS). CMS and colistin demonstrate a low V d and have mixed elimination routes. The V d and CL of colistin may be altered in critically ill patients, potentially affecting colistin exposure. Colistin protein binding in critically ill patients was reported as 59-74% and was concentration dependent [90] .

Colistin demonstrates "concentration-dependent" bactericidal activity, and both in vitro and in vivo data have suggested that the free AUC 0-24 /MIC (fAUC 0-24 /MIC) ratio best predicts its activity. fAUC 0-24 /MIC ratios of 10.9-13.7 and 3.5-9.0 have been described for optimal killing against Pseudomonas aeruginosa and Acinetobacter baumannii, respectively [91] . Prolonged high exposures are associated with neuro-and nephrotoxicity [92] [93] [94] [95] . A C min of > 2.4 mg/L increases the likelihood of colistin-induced nephrotoxicity [92, 96, 97] .

A LD is recommended to compensate for the enlarged V d in critically ill patients with the CMS dosing regimen also adapted to renal function. The variability in conversion from prodrug to active compound, particularly in patients with ARC, makes dosing highly challenging in this patient group, and as such, leading studies on colistin dosing define a singular dose for all creatinine clearance values > 90 mL/min [98] .

The Panel neither recommends, nor discourages routine colistin TDM in critically ill patients.

The therapeutic index for colistin is exceptionally narrow-if TDM is performed, due to the ongoing conversion of CMS to colistin, it is recommended to collect C min samples when CMS concentrations and conversion are at the lowest (i.e. samples to be drawn just before the next dose or C min monitoring), and these samples should be processed immediately. It has been suggested that an average steady-state concentration (C ss ) of 2 mg/L predicts colistin efficacy whilst limiting the likelihood of nephrotoxicity [98, 99] . This target concentration should achieve an fAUC 0-24 /MIC ratio of ~ 12 for pathogens with an MIC of ≤ 2 mg/L, which corresponds to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint for susceptibility. As colistin concentrations are relatively constant with little fluctuations at steady state, this target concentration can also be applied for C min monitoring. However, this target concentration has not been correlated with clinical outcomes.

High-performance liquid chromatography with fluorescence detection (HPLC-FL) and LC-MS/MS assays have been published for colistin TDM.

Polymyxin B demonstrates a low V d and is predominantly cleared via non-renal elimination. Protein binding was high and hugely variable in critically ill patients and was reported as 58-98.4%. Although the PK of polymyxin B is relatively favourable when compared to colistin, current Product Information dosing recommendations may likely lead to sub-optimal drug exposure in critically ill patients.

Polymyxin B demonstrates "concentration-dependent" kill characteristics, and both in vitro and in vivo data have suggested that the fAUC 0-24 /MIC ratio best predicts its activity. fAUC 0-24 /MIC ratios of 3.7-28.0 correlated best with Klebsiella pneumoniae killing [100] , and these indices are in line with those reported for colistin against P. aeruginosa and A. baumannii (3.5-13.9) [91] . A steady-state AUC 0-24 of 100 mg h/L has been proposed as the nephrotoxicity threshold [101] .

Current data suggest that LD of 2.5 mg/kg followed by 1.5-2.5 mg/kg/day (in two divided doses) may be appropriate for pathogens with an MIC of ≤ 1 mg/L [102, 103] . Higher daily doses (up to 3 mg/kg/day), preceded by LD, should be considered for pathogens with an MIC of > 1-2 mg/L. Although it has been generally accepted that IV polymyxin B is best dosed by total body weight, emerging data have since disputed this approach [104] .

The Panel neither recommends, nor discourages routine polymyxin B TDM in critically ill patients.

The therapeutic index for polymyxin B is exceptionally narrow-if performed, AUC-based TDM (50-100 mg h/L) with at least one sample collected (concentrations at 12-24 h post-initiation of therapy) combined with Bayesian dose adaptation has been suggested to optimise polymyxin B dosing in critically ill patients [101, 102] .

LC-MS/MS assays have been published for polymyxin B TDM.

The echinocandin antifungals include anidulafungin, caspofungin and micafungin, which are only available for parenteral use. The echinocandins have high plasma protein binding (≥ 97-99%). Exposure in critically ill patients is generally lower and more variable compared to healthy volunteers, but the clinical implication of this is unclear due to the heterogeneous case mix and small sample sizes in these studies.

Echinocandin exposures relating to optimal clinical outcomes and toxicity occurrence have not been identified thus far. However, optimal mycological response for micafungin against Candida spp. has been observed in patients with AUC 0-24 /MIC ratios of > 3000 [105] .

Although echinocandins are presumed to be clinically comparable with each other, subtle dosing differences exist, e.g. the need for a loading dose, metabolic route and drug-drug interactions. Higher body weight may require higher dosing [106] [107] [108] . Echinocandin exposure can be influenced in patients with severe hepatic impairment, particularly for caspofungin. Lower exposure, as well as higher exposure, has been observed in these patients [109] [110] [111] .

The Panel neither recommends, nor discourages routine echinocandin TDM in critically ill patients.

LC-MS/MS assays have been published but are sparsely implemented for routine TDM.

Fluconazole is available for parenteral and oral administration, is well absorbed from the gastrointestinal tract and displays linear PK. It is moderately lipophilic, demonstrates a V d of around 1 L/kg and is predominantly cleared via renal elimination. Significant inter-individual PK variability has been observed in critically ill patients.

Maximal clinical efficacy in patients with candidemia has been described with AUC 0-24 /MIC ratios of ≥ 55.2-100 [112, 113] . As the dose can be used as a surrogate for fluconazole AUC [114] , the ratio of dose to MIC (dose/ MIC) has also been used to describe clinical outcomes [112, 113, 115] . Higher dosing may likely lead to hepatotoxicity and seizures [116] .

LD of 12 mg/kg IV followed by a maintenance dose (MD) of 6 or 12 mg/kg/day IV is advocated to achieve either the low (AUC 0-24 /MIC ratio of 25) or high (AUC 0-24 /MIC ratio of 100) PK/PD target, respectively, in critically ill patients with normal renal function [117] .

The Panel neither recommends, nor discourages routine fluconazole TDM in critically ill patients.

Several chromatographic assays have been published for fluconazole TDM.

Flucytosine's V d ranges from 0.6 to 0.9 L/kg and is predominantly cleared via renal elimination. Significant inter-patient PK variability has been observed, leading to variable flucytosine concentrations.

A C max of > 100 mg/L has been associated with hepatotoxicity and myelosuppression in several clinical studies [118] [119] [120] [121] . Concentrations of < 25 mg/L may selectively amplify resistant C. albicans mutants [122] .

There are insufficient clinical data to support altering flucytosine dosing for maximal outcomes in critically ill patients. Standard, weight-based dosing, adapted to renal function, is appropriate.

The Panel neither recommends, nor discourages routine flucytosine TDM in critically ill patients.

TDM-guided dosing to optimise flucytosine efficacy remains poorly described as opposed to prevention of toxicity. If TDM is performed, a C max of < 100 mg/L and C min of ≥ 25 mg/L can be used to prevent flucytosine toxicity and resistance, respectively.

Several chromatographic assays have been published for flucytosine TDM.

Isavuconazole is available in oral (capsule) and IV formulations, and switching between these formulations is acceptable. It has a large V d , and its CL is highly dependent on hepatic metabolism. Plasma protein binding is high (> 99%). It displays linear and favourable PK compared to the other triazoles. Exposures in real-world clinical settings are very similar to those described in clinical trials with > 90% of patients receiving standard isavuconazole dosing expected to achieve a proposed therapeutic concentration of 1 mg/L [123, 124] .

Current data do not identify any significant relationship between isavuconazole exposure with clinical efficacy and safety end points.

LD of 200 mg IV 8 hourly for six doses (or 48 h) followed by MD of 200 mg IV once daily is recommended to achieve an effective C ss by day 3 of treatment.

The Panel neither recommends, nor discourages routine isavuconazole TDM in critically ill patients.

HPLC-UV and LC/MS-MS assays have been published for isavuconazole monitoring.

Itraconazole is available in oral (capsule/tablet and oral solution) and IV formulations. It has 30% higher bioavailability as an oral solution and is more preferred to capsule/tablet formulations. It is lipophilic, demonstrates a large V d and is predominantly cleared via hepatic metabolism. Plasma protein binding is high (> 99%). Itraconazole displays variable and nonlinear PK. There are few data available concerning the use of itraconazole in critically ill patients, although continuous haemodiafiltration results in increased itraconazole elimination [125] .

Higher itraconazole C min has been associated with clinical outcome benefits in Aspergillus spp. [126] , Cryptococcus neoformans [127, 128] and Histoplasma capsulatum infections [129] . During itraconazole prophylaxis, breakthrough infections and mortality are more likely in neutropenic patients with a C min of < 0.25-0.5 mg/L [130] [131] [132] . Oropharyngeal and oesophageal candidiasis patients demonstrated better clinical responses when itraconazole concentrations are > 0.6-1 mg/L [133, 134] . An average concentration of ≥ 17.1 mg/L has been linked with itraconazole toxicity [135, 136] .

LD of 200 mg IV 8 hourly for nine doses (or 72 h) followed by MD of 200 mg IV once or twice daily is recommended to achieve target concentrations within the first few days of therapy.

The Panel neither recommends, nor discourages routine itraconazole TDM in critically ill patients.

Apart from demonstrating nonlinear PK [137] , its high variability in bioavailability and hepatic metabolism together with a less favourable safety profile when compared to other azoles traditionally support itraconazole TDM. A C min target between 0.5 and 1 mg/L is used to guide both prophylaxis and treatment of invasive fungal infections.

Several LC-MS/MS assays have been published for itraconazole TDM.

Posaconazole is available as an oral suspension, tablet and IV formulations. It is lipophilic, demonstrates a large V d and is predominantly cleared via hepatic glucuronidation. Plasma protein binding is high (> 98%). Extreme inter-and intra-individual PK variability and, consequently, sub-optimal exposures are typically seen with the oral suspension [138] [139] [140] [141] [142] .

Higher C min (> 0.5-0.7 mg/L) has been associated with reduced breakthrough infections in patients receiving posaconazole prophylaxis [143] [144] [145] [146] [147] [148] [149] [150] . Patients with invasive aspergillosis demonstrated improved clinical response with an average posaconazole concentration of > 1 mg/L [151, 152] . Exposure-related toxicity has not been described for posaconazole although the European Medicines Agency (EMA), and most clinical studies have suggested a putative C min threshold of > 3.75-4 mg/L [153] , which has yet to be validated clinically.

LD of 300 mg IV every 12 hourly on day 1 followed by MD of 300 mg IV once daily is recommended for invasive fungal infections.

The Panel neither recommends, nor discourages routine posaconazole TDM in critically ill patients.

Although extensive PK variability has been previously described, the newer delayed-release oral tablets and IV formulations increase the likelihood therapeutic targets will be achieved [138, [154] [155] [156] . However, recent data still report highly variable PK in critically ill patients, even with IV posaconazole [157] , and therefore TDM may still be useful in this population. Because of the long half-life of the drug (16-35 h) [158] , a concentration obtained at a random time with respect to the previous dose, including a C min , is approximately representative of the average daily concentration (C ave ) and is accepted as a surrogate for AUC. If TDM is performed, a steady-state C ave target of > 0.5-0.7 mg/L and > 1 mg/L can be used to guide posaconazole prophylaxis and treatment of invasive fungal infections, respectively, particularly when oral suspension is used.

Several chromatographic assays have been published for posaconazole TDM.

Voriconazole is lipophilic, demonstrates a large V d and is predominantly cleared via hepatic metabolism. Plasma protein binding is 58%. Voriconazole displays nonlinear PK in adults and exhibits extensive inter-individual PK variability in all patient populations.

A C min of ≥ 1 [159] [160] [161] [162] [163] [164] [165] or ≥ 2 mg/L [166] [167] [168] , as well as a C min to MIC (C min /MIC) ratio of 2-5 [169] , has been associated with improved clinical outcomes in the treatment of invasive fungal infections. Although no clear exposure-response relationship has been established for voriconazole prophylaxis, breakthrough fungal infections are reported to be more likely with a C min of ≤ 1.5-2 mg/L [170, 171] . C min of ≥ 4.5-6 mg/L has been linked with voriconazole-associated hepatotoxicity and neurotoxicity [161, 165, 167, [172] [173] [174] [175] .

LD of 6 mg/kg IV every 12 hourly for two doses followed by 3-4 mg/kg IV 12-hourly is recommended for invasive fungal infections.

The Panel recommends that TDM be routinely performed when voriconazole is used in critically ill patients.

TDM-guided voriconazole dosing in the treatment of invasive fungal infections has been shown to improve clinical response and reduce voriconazole discontinuation due to adverse events [163] . Limited data are available in critically ill patients, but sub-optimal exposures and negative clinical outcomes have been observed in these patients with standard voriconazole dosing [160] . Also, recent publications reported the significant role of the inflammatory response in the unpredictable PK of voriconazole with a 0.015 mg/L rise in the C min for every 1 mg/L increase in C-reactive protein (CRP) [176] [177] [178] . As inflammation is common in critically ill patients, this could have a significant impact on the incidence of voriconazole toxicities. A C min target between 2 and 6 mg/L is recommended to guide voriconazole dosing.

Several chromatographic assays have been published for voriconazole TDM.

Valaciclovir is the orally administered prodrug of aciclovir, which is moderately lipophilic, demonstrates a large V d and is predominantly cleared via renal elimination.

Limited data exist linking aciclovir exposures with clinical efficacy and toxicity. Although the efficacy of aciclovir/valaciclovir in the treatment of herpes simplex virus (HSV) infection has been associated with AUC and the time that the drug remains above the 50% inhibitory concentration (EC 50 ; T > EC 50 ) [179] [180] [181] [182] [183] , these indices require further investigations. Higher concentrations, particularly in patients with renal impairment, have been linked with the likelihood of gastrointestinal and neurological adverse events [184] [185] [186] [187] .

A standard dose of 10-15 mg/kg IV 8 hourly is recommended for severe viral infections in immunocompetent patients.

The Panel neither recommends, nor discourages routine aciclovir TDM in critically ill patients.

Few reports are available on aciclovir TDM, and most of them included patients with encephalitis [188, 189] . A C min of 2-4 mg/L can be recommended if TDM is performed.

Several HPLC-UV and LCMS-MS assays have been published for aciclovir TDM.

Significant inter-and intra-individual PK variability has been reported, and it may be challenging to estimate foscarnet concentrations over time in an individual patient accurately.

No clear relationship has been established so far between its concentration and clinical efficacy. Most investigators have suggested maintaining plasma concentrations between an arbitrary range of 300-500 µmol/L to ensure that effective antiviral activity is achieved and sustained. Although several small-scale clinical studies have reported that clinical response (e.g. progression of CMV retinitis in HIV patients) and nephrotoxicity can be predicted by the AUC [190] [191] [192] [193] [194] , the therapeutic exposure range of foscarnet remains undefined.

There are insufficient clinical data to support altering foscarnet dosing for maximal outcomes in critically ill patients. Standard, weight-based dosing, adapted to renal function, depending on the indication is appropriate.

The Panel neither recommends, nor discourages routine foscarnet TDM in critically ill patients.

Several HPLC-UV methods have been published to determine foscarnet concentration in biological fluids.

Valganciclovir is the prodrug of ganciclovir, which is hydrophilic, demonstrates a low V d (0.7 L/kg) and is predominantly cleared via renal elimination. The PK of ganciclovir/valganciclovir appears to be predictable with minimal unexplained inter-patient variability in solid organ transplant recipients. There is concern that plasma PK exposures may not be an accurate surrogate marker for intracellular concentrations to predict clinical response and toxicity [195, 196] .

No clear relationship has been established between ganciclovir exposures with clinical efficacy and toxicity. AUC 0-24 has been associated with ganciclovir antiviral activity with values of ≥ 40-60 mg h/L advocated for CMV prophylaxis [197] [198] [199] [200] [201] . C min has also been used to predict ganciclovir activity, but the optimal cut-off value remains poorly defined [202] [203] [204] [205] [206] [207] . No clearly defined toxicity thresholds have been described for ganciclovir, but higher C min and AUC 0-24 values are likely to increase the risk of haematological and neurological toxicity [199, 208] .

In the treatment of CMV infections in immunocompromised patients, the usual dose of ganciclovir for induction therapy is 5 mg/kg IV every 12 hourly which is then followed by 5 mg/kg as a single daily infusion for maintenance therapy.

The Panel neither recommends, nor discourages routine ganciclovir/valganciclovir TDM in critically ill patients.

Several centres have reported their experience with ganciclovir/valganciclovir TDM [208, 209] , even though changes in immunological markers have been reported to predict clinical outcomes reliably [210, 211] . A C min of > 2 mg/L or AUC 0-24 of > 40 mg h/L can be applied if TDM is performed. A clinically applicable LSS to estimate ganciclovir/valganciclovir AUC 0-24 has been described [24] and combined with Bayesian dose adaptation; this approach demonstrated superior PK/PD outcomes and trends towards patient benefits when compared to standard dosing recommendations [208] .

Several HPLC-UV and LC/MS-MS assays have been published for ganciclovir/valganciclovir TDM.

Oseltamivir is hydrophilic, demonstrates a large V d and is predominantly cleared via renal elimination. Its active metabolite, oseltamivir carboxylate (OC), displays minimal inter-and intra-individual PK.

No clear relationship has been established between oseltamivir and OC exposures with either clinical efficacy or toxicity. Although the efficacy of oseltamivir in animal models of influenza appears to be dose dependent, no formal exposure-response relationships have been established [212] [213] [214] . It has been suggested that the AUC 0-24 or AUC 0-24 /EC 50 might be suitable indices to guide therapy, but further studies are warranted to validate the clinical relevance of these findings [215, 216] . Higher AUC 0-12 OC exposures have been associated with mild-tomoderate adverse events [217] . The PK of OC appears to be predictable, although this has been mostly determined in healthy volunteers where PK variability is known to be low [217, 218] .

A dose of 75 mg PO once or twice daily is currently recommended for prophylaxis and treatment of influenza in critically ill patients.

The Panel neither recommends, nor discourages routine oseltamivir TDM in critically ill patients.

Although there are limited clinical data to support oseltamivir TDM, French investigators have recently described the utility of paracetamol absorption test to predict OC absorption and likely plasma concentrations in critically ill patients [219] .

Several HPLC-UV and LC/MS-MS assays have been published for oseltamivir TDM.

Ribavirin demonstrates a large V d (≥ 18 L/kg) and is predominantly cleared via renal elimination. Wide interindividual PK variability, including bioavailability, has been reported with this drug.

Inconsistent data have been reported on the relationship between ribavirin exposure and efficacy, as well as toxicity occurrence. Although higher C min [220] [221] [222] [223] [224] [225] [226] and AUC [225, 227, 228] values have been associated with eradication of hepatitis C virus (HCV) or sustained virological response in some studies, it is important to note that numerous studies have also shown no association between these parameters and sustained virological response. It has been suggested that the AUC 0-4 (1.76 mg h/L) and AUC 0-12 (3.01 mg h/L) after the first dose may be a better sustained virological response predictor when compared to C min or any single time point [228] . Although haemolytic anaemia has been linked with a C min of > 2.3-3.5 [224, 229, 230] , some studies have found no significant correlation. Additionally, other studies indicated that other factors (e.g. pegIFN-alpha-2a levels) may have a greater impact on the outcome than ribavirin concentrations [231] .

The Panel neither recommends, nor discourages routine ribavirin TDM in critically ill patients.

Ribavirin TDM has been controversially discussed for at least a decade since hepatitis C is no longer treated as a pathogenic entity but rather according to different genotypes, and old combination partners are no longer state of the art. Furthermore, there is currently conflicting data regarding the relationship between ribavirin exposures with therapeutic or toxic effects. However, it is important to note that as opposed to weight-based dosing, TDMguided ribavirin dosing has been shown to significantly improve sustained virological response in patients with chronic hepatitis C genotype 1 [227] . Although anaemia was more severe in the TDM group, it was well managed with erythropoietin beta. More recently, TDM has been suggested as a useful tool to guide ribavirin treatment in lung transplant recipients with paramyxovirus infection [232] .

Several HPLC-UV and LC/MS-MS assays have been published for ribavirin TDM.

Optimal antimicrobial exposures and PK/PD targets in the treatment of sepsis and septic shock in ICU Optimal intravenous antimicrobial therapy needs to be administered as soon as possible, preferably within the first hour of sepsis and septic shock recognition [233] . Empirical antimicrobial therapy should attempt to provide coverage against all likely pathogens (bacterial, fungal and/or viral) and effective exposures are needed in the interstitial fluid of tissues presumed to be the source of infection. As extreme pathophysiological changes are likely to affect antimicrobial exposures, factors associated with PK/PD alterations need to be determined and considered in critically ill patients with sepsis and septic shock. Optimal antimicrobial exposures and PK/PD targets for patient benefits need to be further elucidated before appropriate dosing regimens and strategies can be improved in this population. The role of biomarkers as a surrogate for an antimicrobial response should be investigated as an earlier therapeutic intervention can be made rather than relying on clinical signs and symptoms [234, 235] . More data on plasma and target-site tissue PK of antimicrobials, particularly in the first 24 h of therapy, are needed to evaluate the appropriateness of the current dosing regimen in this patient population.

Most of the Panel's treatment goals have been focused on maximising clinical and microbiological outcomes and not including resistance suppression. However, for most antimicrobials, clinical data are urgently needed to define thresholds that can minimise resistance emergence and whether they are safe for patients.

Only a few studies have attempted to compare the clinical outcomes of TDM-guided antimicrobial dosing versus outcomes without this intervention [39, 163, 227] . Currently, most data were obtained from small-scale and uncontrolled studies, which are not of itself, sufficient to support a global practice shift towards routine antimicrobial TDM in ICU. Therefore, well-designed and controlled studies focusing on patient-centred outcomes should be performed in this population to evaluate the real benefits of incorporating TDM into daily ICU practice.

Routine antimicrobial TDM in critically ill patients is currently hampered by slow turnaround times, and even in expert centres, antimicrobial concentrations may only be available after 6-8 h of blood collection, potentially leading to delayed dosing improvements. Furthermore, in most ICUs, TDM is probably not available for all important antimicrobials and certainly, not for 24 h and 7 days a week [5, 6] . An easy-to-use chromatography-based method that enables rapid and reliable simultaneous determination of antimicrobial concentrations in plasma and tissues can be developed, and some are now being used routinely in clinical settings. Although concentration measurements are usually performed in blood matrices (e.g. plasma or serum), several alternative sampling strategies (e.g. dried blood spots and volumetric absorptive microsamples), which are minimally or non-invasive approaches, need to be further investigated and validated for routine TDM in critically ill patients. Importantly, these "patient-friendly" strategies may play an important role in the establishment of TDM centres in remote and resource-limited settings.

Although alternative dosing strategies can improve antimicrobial exposure in critically ill patients, the extreme PK variability in this patient population means that some may still receive sub-optimal antibiotic exposure leading to unpredictable clinical outcomes. TDM-guided dosing is the only safe and effective way to ensure that all critically ill patients achieve therapeutic antimicrobial exposures. TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established and for these agents, routine TDM in critically ill patients may be useful. Specifically, we recommend routine TDM when one of these antibiotics or antifungals is used in critically ill patients: aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole. For the antivirals, urgent research is needed to identify therapeutic targets for patient benefits and to also ascertain whether antiviral TDM is indeed meritorious in this patient population. Although we believe that TDM should be the standard of care for most antimicrobials in every ICU, important barriers, such as the availability of bioanalytical experts and TDM equipments in an institution, need to be addressed before routine TDM can be widely employed worldwide.

Antimicrobial utilisation in 37 Australian and New Zealand intensive care units

International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?

What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review

The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs

An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams

The clinical relevance of plasma protein binding changes

Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review

Augmented renal clearance in critical illness: an important consideration in drug dosing

Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations

Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations

A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance

Association between augmented renal clearance and clinical outcomes in patients receiving beta-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial

Principles of antibacterial dosing in continuous renal replacement therapy

Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study

The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations

Optimising drug dosing in patients receiving extracorporeal membrane oxygenation

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update

National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2013) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention

MIC-based dose adjustment: facts and fables

Pharmacokinetic characteristics and limited sampling strategies for therapeutic drug monitoring of colistin in patients with multidrug-resistant gram-negative bacterial infections

Optimal sparse sampling for estimating ganciclovir/ valganciclovir AUC in solid organ transplant patients using NONMEM

Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis

Proficiency testing for meropenem and piperacillin therapeutic drug monitoring: preliminary results from the Belgian society on infectiology and clinical microbiology pharmacokinetic-pharmacodynamic working group

Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations

Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration

New regimen for continuous infusion of vancomycin in critically Ill patients

Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach

Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing

Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting

Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients

Therapeutic drug monitoring of amikacin in septic patients

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial

Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen

Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients

Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis

A suggested approach to oncedaily aminoglycoside dosing

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

Pharmacodynamics of cefepime in patients with Gram-negative infections

Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia

French Network of Pharmacovigilance Centres (2019) Betalactam-induced severe neutropaenia: a descriptive study

Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and metaanalysis of randomised trials

Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures

Pharmacodynamic target attainment for cefepime, meropenem, and piperacillintazobactam using a pharmacokinetic/pharmacodynamic-based dosing calculator in critically ill patients

Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy

Trimethoprim-sulfamethoxazole pharmacokinetics in trauma patients

Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?

Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

Population pharmacokinetics of daptomycin in critically ill patients

Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

Staphylococcus aureus osteo-articular infection: usefulness of the determination of daptomycin serum concentration to explain a treatment failure

Therapeutic drug monitoring of daptomycin: a retrospective monocentric analysis

Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

Convulsions associated with moxifloxacin

Levofloxacin neurotoxicity and non-convulsive status epilepticus (NCSE): a case report

Seizures associated with levofloxacin: case presentation and literature review

Association between oral fluoroquinolones and seizures: a self-controlled case series study

Variability in trough total and unbound teicoplanin concentrations and achievement of therapeutic drug monitoring targets in adult patients with hematological malignancy

Albumin concentration significantly impacts on free teicoplanin plasma concentrations in noncritically ill patients with chronic bone sepsis

Authors DS (2014) Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study

Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections

Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections

Pharmacodynamics of teicoplanin against MRSA

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections

Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest(R) MIC values of 1.5 mg/L: a pilot study

Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia

Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureusassociated septic shock

Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia

Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta-analysis

Continuous versus intermittent infusion of vancomycin for the treatment of Grampositive infections: systematic review and meta-analysis

Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population

A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity

Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC >/= 400 in patients with presumed MRSA infection?

Are vancomycin trough concentrations adequate for optimal dosing?

Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia

Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme

Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients

Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis

Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis

Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill

New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection

Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients

Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin

Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system

Risk factors for colistin-associated nephrotoxicity

Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate

Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

Updated US and European dose recommendations for intravenous colistin: how do they perform?

Dosing guidance for intravenous colistin in critically-ill patients

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models

Personalizing polymyxin B dosing using an adaptive feedback control algorithm

Population pharmacokinetics of polymyxin B in acutely ill adult patients

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens

Population pharmacokinetics of intravenous polymyxin B from clinical Samples

Use of pharmacokineticpharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia

Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients

Low caspofungin exposure in patients in intensive care units

Does weight impact anidulafungin pharmacokinetics?

Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure

Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction

Single-and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia

Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia

Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections

Effect of obesity on the population pharmacokinetics of fluconazole in critically ill patients

Flucytosine: correlation between toxicity and pharmacokinetic parameters

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis

Alling DW (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis

Bone marrow toxicity associated with 5-fluorocytosine therapy

In vitro studies of 5-fluorocytosine resistance in Candida albicans and Torulopsis glabrata

Isavuconazole concentration in real-world practice: consistency with results from clinical trials

Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to aspergillus and other filamentous fungi

Itraconazole concentrations during continuous haemodiafiltration

Treatment of invasive aspergillosis with itraconazole

High-dose itraconazole in the treatment of severe mycoses

Itraconazole therapy for cryptococcal meningitis and cryptococcosis

Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole

Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels

Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies

Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules

Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis

Tremor: a newly described adverse event with long-term itraconazole therapy

Toxicodynamics of itraconazole: implications for therapeutic drug monitoring

Pharmacokinetics of itraconazole following oral administration to normal volunteers

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study

Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease

Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis

Posaconazole plasma concentrations in critically ill patients

Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations

Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis

Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections

Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake

Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies

Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease

A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis

Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy

Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease

Pharmacokinetics of intravenous posaconazole in critically ill patients

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

Observational study of associations between voriconazole therapeutic drug monitoring, toxicity, and outcome in liver transplant patients

Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies

Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring

Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokineticsbased analysis of adult patients with invasive fungal infections

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

Voriconazole concentrations and outcome of invasive fungal infections

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

Voriconazole therapeutic drug monitoring

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole

Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity

Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients

Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes

Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring

Voriconazole metabolism is influenced by severe inflammation: a prospective study

Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations

Inflammation is associated with voriconazole trough concentrations

Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis

A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

A largescale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers

Acyclovir-induced neurotoxicity: a case report and review of literature

Progressive somnolence leading to coma in a 68-year-old man

Acyclovirinduced neurotoxicity: concentration-side effect relationship in acyclovir overdose

Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster

Valacyclovir for herpes simplex encephalitis

Use of therapeutic drug monitoring in the long-term valaciclovir therapy of relapsing herpes simplex virus encephalitis in children

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS

Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients

Foscarnet for suppression of human immunodeficiency virus replication

Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis

Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS

Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D +/R − transplant recipients

Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients

Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis

Valganciclovir Solid Organ Transplant Study Group (2005) Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

Absence of cytomegalovirusresistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients

Roche Cooperative Oral Ganciclovir Study Group (2002) High dose oral ganciclovir treatment for cytomegalovirus retinitis

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients

Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis

Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group

Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function

Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients

Human pharmacokinetics of the antiviral drug DHPG

Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients

Valganciclovir pharmacokinetics in patients receiving oral prophylaxis following kidney transplantation and model-based predictions of optimal dosing regimens

Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8 + T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients

Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation

Oseltamivir population pharmacokinetics in the ferret: model application for pharmacokinetic/pharmacodynamic study design

Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies

Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system

Pharmacokinetics of high-dose oseltamivir in healthy volunteers

Population pharmacokinetics of oseltamivir when coadministered with probenecid

Paracetamol absorption test to detect poor enteric absorption of oseltamivir in intensive care unit patients with severe influenza: a pilot study

Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV

Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon

Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients

Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C

Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C

Optimizing ribavirin exposure by therapeutic drug monitoring improves treatment response in patients with chronic hepatitis C genotype 1

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients

Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C

Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients

Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens

Surviving sepsis campaign: international guidelines for management of sepsis and septic shock

Pharmacodynamics of isavuconazole for invasive mold disease: role of galactomannan for real-time monitoring of therapeutic response

Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy

We wish to acknowledge the individual societies for their endorsement of this Position Paper. We also wish to acknowledge the members of the public who provided public feedback that was addressed by the Panel as part of the ESCMID endorsement process.